Liver Int 2021 Mar 3. Epub 2021 Mar 3.
Department of Internal Medicine, Weill Cornell College of Medicine, New York and Doha, Qatar.
Minerva Gastroenterol (Torino) 2021 Apr 15. Epub 2021 Apr 15.
Gastro-hepatoloy Unit, Department of Medical Sciences, University of Turin, Turin, Italy -
Background: there is robust epidemiological evidence suggesting the link of chronic Hepatitis C Virus (HCV) infection with type 2 diabetes mellitus (DM). Viral clearance achieved by Direct Acting Antiviral Agents (DAAs) has been associated to significant improvements in glycometabolic control but data on the long-term effect of Sustained Virological Response on diabetic disease are limited.Aim: the aim of this review is to evaluate the influence of SVR after DAA-based therapy on Insulin Resistance (IR) and DM incidence in non-diabetic patients, on the glycemic homeostasis in diabetic patients and on their long-term hepatic and metabolic outcomes. Read More
Dipartimento di Scienze Mediche, Scuola di Medicina, Università degli Studi di Torino, Turin, Italy -
The relationship between HCV infection and extrahepatic manifestations has been demonstrated by epidemiological, clinical, immunological and pathological studies. Patients with HCV infection have an increased risk of morbidity and mortality related to these non-liver diseases. For these reasons, HCV chronic infection should be considered a systemic disease in which extrahepatic manifestations increase the severity of the disease. Read More
Int J Drug Policy 2021 Apr 11:103247. Epub 2021 Apr 11.
Department of Medicine, Division of Infectious Diseases/Chronic Viral Illness Service, Glen site, McGill University Health Centre, 1001, Decarie Boulevard - D02.4110, Montreal, Quebec, H4A 3J1, Canada; CIHR Canadian HIV Trials Network, 588 - 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada. Electronic address:
Background: Direct acting antivirals (DAAs) have increased cure rates for hepatitis C virus (HCV) infection; however, there are several obstacles to the uptake of DAAs in populations where substance use contributes to HCV risk. This synthesis aimed to identify the patient and provider perceived barriers and facilitators to DAA treatment initiation in key patient subgroups-people who inject drugs (PWID), men who have sex with men (MSM), and Indigenous people.Methods: We systematically searched seven databases and conducted a gray literature search for studies that qualitatively explored patient and provider perceived barriers and facilitators to DAA treatment in our populations of interest. Read More
Rev Med Chil 2020 Dec;148(12):1813-1818
Servicio de Medicina Interna, Hospital Clínico, Universidad de Chile, Santiago, Chile.
Hepatitis C virus infection is a major global public health problem. Treatment with direct-acting antivirals is intended to eradicate the chronic form of this infection by 2030. Although uncommon, the acute form of presentation is increasingly recognized, especially in some high-risk populations, such as men who have sex with men without protection. Read More
Braz J Infect Dis 2021 Apr 6:101573. Epub 2021 Apr 6.
University of Brasília (UnB), Faculty of Medicine, Center for Tropical Medicine, Brasília, DF, Brazil; National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil; University of Brasília (UnB), Faculty of Ceilândia, Brasília, DF, Brazil.
A retrospective cohort of 11,308 chronic hepatitis C infected patients treated with regimens that included Sofosbuvir (SOF), Daclatasvir (DCV), Simeprevir (SMV), or an association of Ombitasvir, Veruprevir/Ritonavir and Dasabuvir (3D) with or without Ribavirin (RBV) were assessed for sustained virologic response (SVR) or viral cure after a 12-week treatment. Logistic regression analyses were used to identify factors independently associated with positive response to direct-acting antivirals (DAA)-based therapies. Overall 57. Read More